Compounds and their administration for treating a neurodegenerative disease as well as a method for identifying a compound capable of inhibiting a kinase, such as LRRK

• US 8,569,281 B2
• Filed: 09/21/2011
• Issued: 10/29/2013
• Est. Priority Date: 09/22/2010
• Status: Expired due to Fees

• Current Assignee: Medical Research Council Technology (MRCT), Genentech, Inc. (Roche Holding AG)
• Original Assignee: Medical Research Council Technology (MRCT), Genentech, Inc. (Roche Holding AG)
• Inventors: Chen, Huifen, Chan, Bryan K., Estrada, Anthony, Shore, Daniel, Sweeney, Zachary, McIver, Edward Giles
• Primary Examiner(s): HENLEY III, RAYMOND J
• Application Number:
  US13/238,840
• Publication Number:
  US 20120295883A1
• Time in Patent Office: 769 Days
• Field of Search: 514/210.18, 514/210.21, 514/303, 514/210.8, 546/119, 544/105, 544/127, 544/333, 544/362
• US Class Current: 514/210.08
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07D 471/04 Ortho-condensed systems

Abstract

The present invention relates to substituted pyrazolopyridine compounds, and pharmaceutically acceptable salts or esters thereof. The present invention further relates to therapeutic uses of pharmaceutical compositions comprising the substituted pyrazolopyridine compounds, for example, in cancer and neurodegenerative diseases.

Claims

1. A compound selected from the following:

2. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier, diluent or excipient.

3. A method of treating a neurodegenerative disease, wherein the method comprises administering to a subject in need thereof, a therapeutically effective amount of a compound according to claim 1, thereby treating said neurodegenerative disease.

4. A method of treating a disease alleviated by the inhibition of LRRK2, wherein the method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound according to claim 1, thereby treating said disease.

5. A method for identifying a compound capable of inhibiting LRRK, the method comprising the steps of:

contacting a LRRK with a candidate compound in the presence of a compound according to claim 1; and

detecting interaction between LRRK and the compound according to claim 1, wherein a change in the interaction indicates that the candidate compound is an inhibitor of the LRRK.

6. A combination comprising a compound according to claim 1 and a further therapeutic agent.

7. A pharmaceutical composition according to claim 6 which further comprises a second therapeutic agent.

8. The method according to claim 3, wherein the neurodegenerative disease is Parkinson'"'"'s Disease.

9. The method according to claim 5, wherein the LRRK is LRRK2.